While a consensus exists that rising PTH levels serve as an indication for treatment initiation, it has been suggested that complete normalization of PTH levels is to be avoided [35,36,37], due to the beneficial phosphaturic effects of PTH, the presence of hypo-responsiveness to PTH in CKD and to avoid low turnover bone disease. This evidence concerns the gene PTH and chronic kidney disease.